Cartesian Therapeutics (RNAC) Net Cash Flow (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Net Cash Flow for 12 consecutive years, with -$6.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 79.85% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$61.7 million (down 179.87% YoY), while the FY2025 annual figure was -$87.4 million, down 164.3% from the prior year.
• Net Cash Flow grew to -$6.5 million in Q1 2026 per RNAC's latest filing, from -$18.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $132.0 million in Q3 2024 and bottomed at -$34.0 million in Q3 2023.
• Historically, Net Cash Flow has averaged $291529.4 across 5 years, with a median of -$6.6 million in 2024.
• On a YoY basis, Net Cash Flow climbed as much as 7416.87% in 2022 and fell as far as 992.78% in 2022.
• Cartesian Therapeutics' Net Cash Flow stood at -$6.4 million in 2022, then surged by 57.42% to -$2.7 million in 2023, then plunged by 142.73% to -$6.6 million in 2024, then sank by 177.74% to -$18.3 million in 2025, then jumped by 64.44% to -$6.5 million in 2026.
• Business Quant data shows RNAC's Net Cash Flow at -$6.5 million in Q1 2026, -$18.3 million in Q4 2025, and -$16.9 million in Q3 2025.